Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALG-010133
- Development stage
- Discontinued
- Lead developer
- Aligos Therapeutics
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Aptamers → DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ALG-010133 is an S-antigen Transport Inhibiting Oligonucleotide Polymer (STOPS) molecule developed by Aligos Therapeutics for the treatment of chronic hepatitis B. It is a nucleic acid polymer (NAP), specifically a locked nucleic acid (LNA)-modified oligonucleotide, designed to inhibit the production and release of hepatitis B surface antigen (HBsAg) from infected hepatocytes with high potency in vitro. The drug acts by interacting with host cellular factors involved in RNA processing, translation, and protein folding/degradation, thereby reducing HBsAg levels. Despite promising preclinical results and acceptable safety profiles in early clinical studies, development was discontinued after Phase 1 due to insufficient efficacy at projected therapeutic doses[1][2][3][7].
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on ALG-010133.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALG-010133.